Filana Therapeutics, Inc.

FLNA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-3.5M
Depreciation & Amortization $257.0K
Depreciation —
Amortization —
Stock-Based Compensation $6.7M
Net Cash from Operating Activities $-14.7M
Investing Activities
Capital Expenditures —
Business Acquisitions —
Net Cash from Investing Activities $-103.2M
Financing Activities
Dividends Paid —
Stock Repurchases —
Net Cash from Financing Activities $555.0K
Net Change in Cash $-117.4M
Free Cash Flow —
← Newer Page 3 of 3 Older →